A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age
Public ClinicalTrials.gov record NCT05630846. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Single-blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of a Measles, Mumps, Rubella, Varicella Vaccine Compared With ProQuad, Administered in Healthy Children 4-6 Years of Age
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main purpose of this study is to assess immune response and safety of various potencies of a measles, mumps, rubella, and varicella (MMRVNS) vaccines given to healthy children of 4 to 6 years of age.
Study identification
- NCT ID
- NCT05630846
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 801 participants
Conditions and interventions
Conditions
Interventions
- Investigational MMRV(H)NS vaccine Biological
- Investigational MM(H)RVNS vaccine Biological
- Investigational M(L)M(L)R(L)V(L)NS vaccine Biological
- Marketed MMRV_Lot 1 and Lot 2 vaccine Biological
Biological
Eligibility (public fields only)
- Age range
- 4 Years to 6 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 14, 2022 (Actual)
- Primary completion
- Jun 7, 2024 (Actual)
- Completion
- Oct 14, 2024 (Actual)
- Last update posted
- Jun 22, 2025
2022 – 2024
United States locations
- U.S. sites
- 35
- U.S. states
- 16
- U.S. cities
- 33
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Birmingham | Alabama | 35235 | — |
| GSK Investigational Site | Jonesboro | Arkansas | 72401 | — |
| GSK Investigational Site | Bellflower | California | 90706 | — |
| GSK Investigational Site | Huntington Park | California | 90255 | — |
| GSK Investigational Site | Oakland | California | 94611 | — |
| GSK Investigational Site | Roseville | California | 95661 | — |
| GSK Investigational Site | Sacramento | California | 95815 | — |
| GSK Investigational Site | Sacramento | California | 95823 | — |
| GSK Investigational Site | San Jose | California | 95119 | — |
| GSK Investigational Site | Santa Clara | California | 95051 | — |
| GSK Investigational Site | West Covina | California | 91790 | — |
| GSK Investigational Site | Miami Lakes | Florida | 33014 | — |
| GSK Investigational Site | Tampa | Florida | 33613 | — |
| GSK Investigational Site | Ammon | Idaho | 83406 | — |
| GSK Investigational Site | Idaho Falls | Idaho | 83404 | — |
| GSK Investigational Site | Louisville | Kentucky | 40291 | — |
| GSK Investigational Site | Lafayette | Louisiana | 70508 | — |
| GSK Investigational Site | Boston | Massachusetts | 02118 | — |
| GSK Investigational Site | Bingham Farms | Michigan | 48025 | — |
| GSK Investigational Site | Detroit | Michigan | 48201 | — |
| GSK Investigational Site | Lincoln | Nebraska | 68505 | — |
| GSK Investigational Site | Lincoln | Nebraska | 68522 | — |
| GSK Investigational Site | Omaha | Nebraska | 68114 | — |
| GSK Investigational Site | Syracuse | New York | 13210 | — |
| GSK Investigational Site | Cleveland | Ohio | 44121 | — |
| GSK Investigational Site | Dayton | Ohio | 45414 | — |
| GSK Investigational Site | Simpsonville | South Carolina | 29681 | — |
| GSK Investigational Site | Tullahoma | Tennessee | 37388 | — |
| GSK Investigational Site | Dickinson | Texas | 77539 | — |
| GSK Investigational Site | McAllen | Texas | 78504 | — |
| GSK Investigational Site | Richmond | Texas | 77469 | — |
| GSK Investigational Site | Layton | Utah | 84041 | — |
| GSK Investigational Site | Provo | Utah | 84604 | — |
| GSK Investigational Site | Roy | Utah | 84067 | — |
| GSK Investigational Site | South Jordan | Utah | 84095 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05630846, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 22, 2025 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05630846 live on ClinicalTrials.gov.